And so forth, until soon the vaccine industry is enabled to move to a subscription model where you have to get a new jab every month to keep up with the budding variants, or you won't be allowed out of your house. This is big pharma's chance to grab the biggest brass ring of all, getting entire populations dependent on regular and frequent vaccinations (you might say addicted), and their plan is working.
The Davos elite love the plan, no doubt, because it serves the greater goal of population reduction.
Seems Geert has been mostly right with his predictions since March. If his hypothesis is even partly true, the world as we know will soon be changing. This is not good.
First, that's not me. I don't have COVID so I am not spawning vaccine resistant variants. Second, vaccine resistant strains only affect the vaccinated. You are obviously not vaccinated so why are you worried about it? Third the escape mutations you are talking about come from both vaccinated and unvaccinated patients. There's no difference. Fourth, I am not planning to get another vaccine for any hypothetical vaccine-resistant variants.
This is a pretty frightening article. I think we are already seeing the beginning of a cycle in which the failure of Round 1 (the first group of vaccines) to eradicate the disease will lead to a doubling-down on the approach that has already failed.
we will need constant Big pharma "UPDATES"
Addressing Geert Vanden Bossche’s Claims
Written By Edward Nirenberg
The short version: Geert Vanden Bossche has recently published a letter in which he argues that the vaccination campaign against COVID-19 is going to precipitate a public health disaster because the vaccines will select for viral variants that can escape their protection and drive them towards higher virulence. His claims are speculative, he offers no evidence to support his arguments, and makes several comments which are blatantly incorrect. The core of his argument relies on the assumption that COVID-19 vaccines do not have a significant effect on transmission. This has been repeatedly confirmed to be false in multiple studies. Furthermore, even if his assumptions about the effects of the vaccine on transmission are true, his conclusions are incorrect based on established precedent from Marek’s disease, a viral illness of birds with a vaccine that does not strongly affect transmission- but it still shows meaningful public health benefits in the populations of chickens where it is used. The vaccines will absolutely be critical to ending the pandemic, and fortunately the modular nature of the technology allows for rapid reformulation and adjustment as necessary (and thus far, though precautions are being taken with novel variants to produce vaccines specific to their set of problematic mutations, there isn’t significant enough evidence to suggest that total reformulation of the vaccines is needed), but no issues raised in this letter warrant a re-evaluation of our current COVID-19 vaccination policy.
(more at the link)
https://www.deplatformdisease.com/blog/addressing-geert-vanden-bossches-claims
would prefer open debate about this. No symposium, no trust in those who benefit from their own research.
At the rate that vaxxed are dying, shouldn’t be a problem for more than two or three years.
So all of a sudden vaccines are bad and we should let every infectious disease to just run it’s course.
The stupid here is unbeleivable.
Ego, ambition, and turmoil: Inside one of biotech’s most secretive startups
Written in 2016.
Before the jabs.
Before the stolen election.
Before the China bioweapon.
Before OrangeManBad was elected.
Money quote:
"But interviews with more than 20 current and former employees and associates suggest Bancel has hampered progress at Moderna because of his ego, his need to assert control and his impatience with the setbacks that are an inevitable part of science. Moderna is worth more than any other private biotech in the US, and former employees said they felt that Bancel prized the company’s ever-increasing valuation, now approaching $5 billion, over its science." (snip)
"Lower-ranking employees, meanwhile, said they’ve been disappointed and confused by Moderna’s pivot to less ambitious — and less transformative — treatments. Moderna has pushed off projects meant to upend the drug industry to focus first on the less daunting (and most likely, far less lucrative) field of vaccines — though it is years behind competitors in that arena."